ArticleOpen life sciences2025
Knockdown of SHP-2 delays renal tubular epithelial cell injury in diabetic nephropathy by inhibiting NLRP3 inflammasome-mediated pyroptosis.
Article in Open life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Src homology phosphotyrosyl phosphatase 2 (SHP-2) has been implicated in the pathogenesis of diabetic nephropathy (DN), while pyroptosis, an inflammatory form of programmed cell death, has also been associated with disease progression. However, the regulatory interplay between SHP-2 and pyroptosis in DN remains incompletely understood. In this study, we established DN rat models using a single intraperitoneal injection of streptozotocin (STZ) and HK-2 cells cultured under high-glucose (HG) conditions. Hematoxylin and eosin staining was performed to assess the histopathological changes in renal tissues, while immunofluorescence and Western blotting were used to evaluate SHP-2 and NLRP3 expression in both rat kidney tissues and HK-2 cells. Lentiviral transfection was performed to overexpress SHP-2 or NLRP3, following which the expression of pyroptosis-related proteins, activation of the NLRP3 inflammasome, and cell apoptosis were assessed by Western blot and flow cytometry. The results demonstrated that STZ-treated rats exhibited significant weight loss, hyperglycemia, and renal tissue injury. We observed an increase in SHP-2 expression in the kidney tissues of DN rats and in HK-2 cells exposed to high glucose, along with an elevated expression of NLRP3. SHP-2 knockdown suppressed NLRP3 inflammasome activation and mitigated HG-induced pyroptosis in renal tubular epithelial cells. Notably, overexpression of NLRP3 partially reversed the protective effects conferred by SHP-2 knockdown. These findings suggest that SHP-2 knockdown alleviates renal tubular epithelial cell injury in DN by inhibiting NLRP3 inflammasome-mediated pyroptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.